Clinical Presentation and Laboratory Characteristics in Acute and Recurrent Erysipelas by Brishkoska-Boshkovski, Vesna et al.
 _______________________________________________________________________________________________________________________________ 
Open Access Maced J Med Sci. 2019 Mar 15; 7(5):771-774.                                                                                                                                                        771 
 
ID Design Press, Skopje, Republic of Macedonia 
Open Access Macedonian Journal of Medical Sciences. 2019 Mar 15; 7(5):771-774. 
https://doi.org/10.3889/oamjms.2019.213 
eISSN: 1857-9655 
Clinical Science 
 
 
  
 
Clinical Presentation and Laboratory Characteristics in Acute 
and Recurrent Erysipelas 
 
 
Vesna Brishkoska-Boshkovski
1*
, Irena Dimitrovska
1
, Irena Kondova-Topuzovska
2
 
 
1
Department of Dermatology, City General Hospital 8th September, Skopje, Republic of Macedonia; 
2
University Infectious 
Diseases Clinic, Medical Faculty, Ss Cyril and Methodius University of Skopje, Skopje Republic of Macedonia 
 
Citation: Brishkoska-Boshkovski V, Dimitrovska I, 
Kondova-Topuzovska I. Clinical Presentation and 
Laboratory Characteristics in Acute and Recurrent 
Erysipelas. Open Access Maced J Med Sci. 2019 Mar 15; 
7(5):771-774. https://doi.org/10.3889/oamjms.2019.213 
Keywords: Erysipelas; Recurrent erysipelas; Lower leg 
*Correspondence: Vesna Brishkoska-Boshkovski. 
Department of Dermatology, City General Hospital “8th 
September” Skopje, Republic of Macedonia. E-mail: 
vbrishkoska@yahoo.com 
Received: 15-Feb-2019; Revised: 12-Mar-2019; 
Accepted: 13-Mar-2019; Online first: 14-Mar-2019 
Copyright: © 2019 Vesna Brishkoska-Boshkovski, Irena 
Dimitrovska, Irena Kondova-Topuzovska. This is an open-
access article distributed under the terms of the Creative 
Commons Attribution-NonCommercial 4.0 International 
License (CC BY-NC 4.0) 
Funding: This research did not receive any financial 
support 
Competing Interests: The authors have declared that no 
competing interests exist 
 
 
 
 
 
 
 
 
 
Abstract 
AIM: Typical feature of erysipelas, especially on the lower limbs, is the tendency to reoccur. The study aimed to 
identify clinical and laboratory characteristics of acute and recurrent erysipelas. 
MATERIAL AND METHODS: We prospectively included patients diagnosed with erysipelas on the lower limbs in 
the period from January 2016 to December 2017. Patients were divided into two groups: patients with the first 
episode and recurrent erysipelas. The groups were compared by their demographics, clinical and laboratory 
characteristics. 
RESULTS: The study included 187 patients with the first episode of erysipelas and 126 patients with recurrent 
erysipelas. Both groups were homogeneous in terms of demographic characteristics, gender and age. Mean age 
of patients with the first episode of erysipelas was 64.18 ± 12.5 years; patients with recurrent erysipelas were 
inconsiderably mean younger (62.98 ± 12.5 years). Patients in both groups had a significantly different anatomical 
localisation of skin infection (p = 0.008). Tibial localisation was more frequent in patients with the first episode of 
erysipelas 77% vs 62.7%, while recurrent erysipelas was more frequent on the foot 36.5% vs 23%. No significant 
difference was found, about the affected side of the limb (p = 0.95). Patients with recurrent erysipelas had a 
pronounced inflammatory response, seen through significantly higher values of C reactive protein (p = 0.02), 
granulocytes (p = 0.03), fibrinogen (p < 0.0001), and higher body temperature, (37.22 ± 0.97 p = 0.006). Length of 
hospital stay was increased in the recurrent group.  
CONCLUSION: Erysipelas is more frequent in older people; it has seasonal character and tendency to reoccur. 
Identifying clinical and laboratories characteristics of those at risk may prevent recurrence and long term 
comorbidities. 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
Erysipelas is an infectious disease caused 
most often by β – hemolytic streptococci group A 
(Streptococcus pyogenes), rarely by streptococci 
groups B, C, G and occasionally Staphylococci [1]. It’s 
a common condition, characterised with a warm, 
painful well-demarkated area of erythema – oedema, 
with prominent lymphatic involvement [2]. Systemic 
manifestation such as fever chills regional 
lymphadenopathy and leukocytosis are sometimes 
present and may occur hours before the skin 
abnormalities appear [3]. The diagnosis of soft tissue 
infections relies basically on the clinical picture [3]. 
Studies have shown that erysipelas is a potentially 
serious infection often resulting in recurrence, long-
term morbidity and prolonged hospital stay. The most 
common site of erysipelas is lower legs [4], [5], 
although any area of the body can be affected. Its 
presentation on the lower legs, usually is unilaterally 
[6]. Predisposing factors include chronic 
oedema/lymphoedema, chronic venous insufficiency, 
obesity, any disruption of cutaneous barrier as 
possible sites of bacterial colonisation, previous 
episode of erysipelas, diabetes and immune 
suppression [5], [6], 7]. Complications occur in nearly 
31% of cases [8] and generally present as recurrent 
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erysipelas, abscesses, necrotising fasciitis, phlegmon, 
deep venous thrombosis, skin ulcers and bacteremia 
[9]. Recurrence is a common complication, the 
percentage of recurrence is around 12-29% [4], [10]. 
The mainstay of the treatment is systemic antibiotics. 
In recurrent cases, long term antibiotic prophylaxis is 
recommended [3], [11] but also a vigorous control of 
the risk factors can reduce the rate of reoccurrence. 
The aim of the study was a prospective analysis and 
comparison of patients with acute and recurrent 
erysipelas, with particular consideration of 
demographic, clinical and laboratory characteristics in 
both studied groups. 
 
 
Material and Methods  
 
All patients ≥ 18 years of age both 
hospitalised and outpatients, diagnosed with 
erysipelas on lower legs were recruited in the study, 
between January 2016 and December 2017 in the 
dermatology department in General Hospital in 
Skopje. The diagnosis was clinical, made by the 
investigator.  
The patients were divided into two cohorts. 
First cohort – patients with a first and single episode 
of erysipelas (no recurrence group – NR). Second 
cohort – patients with recurrent erysipelas (RE). NR – 
in this group erysipelas was defined as diffuse, 
superficial skin infection, which causes acute 
erythema, swelling and pain [3]. RE included patients 
with second/multiple episodes of erysipelas that 
meets the criteria of the first episode, at the same 
anatomical localisation, at least 1 month to one year 
from the initial diagnosis. In this group patients with 
anamnestic or medical records for recurrence in or 
outside the study were also included. The required 
data for all recruited patients were obtained through 
clinical examination and patient interview, as well as 
medical documentation.  
The analysed data included demographic 
characteristic (age, sex), the season of erysipelas 
occurrence, clinical characteristic of erysipelas, length 
of hospitalisation, initial values of laboratory 
parameters. These two groups will be compared 
based on their demographic characteristics, clinical 
manifestations, laboratory findings. For the statistical 
analysis, the necessary percentages were computed 
and linear regression analyses performed. For 
continuous variables that were normally distributed 
the mean and standard deviations were presented. 
For non-continuous data, the median was presented. 
Categorical variables were tested with chi-square and 
logistic regression. The statistical significance was 
defined at p < 0.05. 
 
Results  
 
Comparison of demographic, clinical and 
laboratory characteristics between the two 
cohort 
The study included 187 with a first/single 
episode of erysipelas (NR group) and 126 with 
recurrent erysipelas (RE). Both groups were 
homogeneous in terms of demographic characteristics 
sex and age (p = 0.64, p = 0.4 consecutive) (Table 1). 
Male patients were insignificantly more frequently 
presented in the RE group-52.4% (66), 46.5% (87), 
while female patients were insignificantly more 
common in the NR-53.5% (100) and 47.6% (60). 
Table 1: Comparison of demographic and clinical features in 
both cohorts 
Variable 
NR group 
Patients with the first 
episode of erysipelas 
RE group 
Patients with recurrent 
erysipelas 
P-value 
Age n (%) 
Mean ± SD 64.18 ± 12.5 62.98 ± 12.5 
B
p = 0.4 
Min - max 26 – 86 33 – 88 
Gender n (%) 
Male 87 (46.52) 66 (52.38) 
A
p = 0.64 
Female 100 (53.48) 60 (47.62) 
Patient included in the study n (%) 
Hospitalized 152 (81.28) 105 (83.33) 
A
p = 0.64 
Outpatient 35 (18.72) 21 (16.67) 
Length of hospital stays (LOS) n (%) 
Mean ± SD 7.43 ± 4.3 8.35 ± 5.0 
B
p = 0.12 
Min - max 1 – 28 2 – 30 
Febrility n (%) 
Mean ± SD 36.94 ± 0.78 37.22 ± 0.97 
B
p = 0.006 
Min - max 36 – 40 36 – 40.2 
Anatomical localisation of erysipelas (%) 
Tibial 144 (77.01) 79 (62.7) 
A
p = 0.008 
 Foot 43 (22.99) 46 (36.51) 
Femoral region 0 1 (0.79) 
The side of affected extremity (%) 
Right 77 (41.18) 54 (42.86) 
A
p = 0.95 
Left 91 (48.66) 59 (46.83) 
Billateral 19 (10.16) 13 (10.32)  
 
The mean age of patients with the first 
episode of erysipelas was 64.18 ± 12.5 years, and 
patients with recurrent erysipelas were insignificantly 
younger (62.98 ± 12.5 years). 
Most patients in both groups were 
hospitalized-81.3% (152) patients in NR group and 
83.3% (105) patients with RE (p = 0.64) (Table 1). The 
length of hospitalisation was significantly lower in the 
NR group (7.43 ± 4.3 vs 8.35 ± 5.0, p = 0.12). 
Recurrent erysipelas located in the lower extremities, 
the high temperature on admission, increased 
markers of inflammation, significantly prolonged the 
hospital stay. 
Recruited patients from both groups (Table 1) 
had a significantly different anatomical localisation of 
erysipelas (p = 0.008). In NR group 77% vs 62.7% of 
patients had tibial localisation, while in patients with 
RE the infection was more often localised on foot - 
36.5% vs 23%. One patient had erysipelas in the 
femoral region, and it was recurrent. About 10% of 
patients in both groups had bilateral erysipelas. More 
frequent was the unilateral left-sided localisation of the 
disease in both groups-48.7% (91) all 46.8% (59). No 
statistically significant difference was found between 
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both groups, regarding the affected side of the limb (p 
= 0.95). Patients with RE had a significantly higher 
value for the febrility, compared with NR group (37.22 
± 60.97 vs 36.94 ± 0.78, p = 0.006). 
Table 2: Comparison of laboratories parameters / inflammatory 
markers in both cohorts  
Variable 
NR group 
Patients with the first 
episode of erysipelas 
RE group 
Patients with recurrent 
erysipelas 
P-value 
C reactive protein 
Mean ± SD 41.94 ± 51.9 56.83 ± 61.9 
B
p = 0.02 
 Min - max 3.02 – 203 3.02 – 203 
Leucocytes 
Mean ± SD 9.61 ± 3.7 10.44 ± 4.4 
B
p = 0.08 
Min - max 2.1 – 28.5 2.2 – 27.86  
Granulocytes 
Mean ± SD 7.05 ± 3.5 7.98 ± 4.1 
B
p = 0.03 
Min - max 0.9 – 26.8 1.1 – 25.18  
Sedimentation rate 
Mean ± SD 123.48 ± 21.3 126.24 ± 20.5 
B
p = 0.25 
Min - max 20 – 175 101 – 173  
Antistreptolysin O (ASO) titer 
Mean ± SD 195.82 ± 289.3 224.31 ± 316.5 
C
p = 0.064 
Min - max 68.3 (50.9-209) 103 (52.5-227)  
Fibrinogen 
Mean ± SD 4.48 ± 2.1 5.66 ± 3.7 
C
p < 0.0001 
Min - max 4 (3.5-5.1) 5.3 (3.9-6.7)  
D dimers 
Mean ± SD 19.35 ± 192.6 12.45 ± 125.5 
C
p = 0.42 
Min - max 0.62 (0.33-1.33) 0.72 (0.35-1.39)  
 
Most of the patient – 72.2% had erythematous 
erysipelas (226 patients), vesiculobullous and 
hemorrhagic erysipelas in the form of ecchymoses or 
purpuras was observed in 27.8% (87) of patients.  
Comparative analysis of the two groups of 
patients in relation to certain laboratory parameters 
(Table 2) showed that patients with RE had 
significantly higher values of C reactive protein 
(CRP)(p = 0.02), granulocytes (p = 0.03), and 
fibrinogen (p < 0.0001), and had a insignificantly 
higher serum leukocyte values (p = 0.08), 
Sedimentation rate (p = 0.25), Antistreptolysin O 
(ASO) titer (p = 0.064), and D dimers (p = 0.42). CRP 
in serum had an average value of 41.94 ± 51.9 in the 
NR group and 56.83 ± 61.9 in the RE group. The 
granulocyte values were on average 7.05 ± 3.5 in the 
NE group, and 7.98 ± 4.1 in the RE group. The mean 
and median values of fibrinogen in the NR group were 
4.48 ± 2.1, 4, and in the RE 5.66 ± 3.7, 5. 
Figure 1 illustrates the percentage of 
erysipelas cases of admissions per season. The 
greatest prevalence of cases admissions (in and 
outpatients) was observed in summer (29.7%) and 
spring (26.8%); for autumn, the prevalence was 
24.6% and lowest in the winter 18.8% (p = 0.9). The 
peak in the summer has been previously reported [7]. 
 
Figure 1: Percentage of erysipelas cases admissions per season 
Discussion 
 
The study confirmed that recurrent erysipelas 
is more common in the elderly population. The mean 
age in both cohorts patients has no significant 
difference, and no significant gender predomination 
has been established, which is consistent with other 
studies [6]. The greatest prevalence of erysipelas was 
found in > 60-year-old patients (more than 60% of the 
cases), and the mean age was 64.18 ± 12.5 year in 
the NR group and 62.98 ± 12.5 years in RE. Recent 
studies have reported a similar mean age [5], [6]. 
Regarding the anatomical localisation, tibial 
localisation was more common with patients with the 
first episode of erysipelas, while patients with 
recurrent erysipelas had more frequent foot location. 
We noted that the latter is in line with other results 
obtained regarding RE-obesity, insulin-dependent 
diabetes and neuropathy (not included in this paper). 
The feet are prone to chronic swelling, especially in 
obese patients, with diabetes where diabetic 
neuropathy and angiopathy may be present. Injuries 
to the feet, especially in neuropathy and 
dermatomycosis, are the point of entry of the infection. 
Patients with RE had a stronger inflammatory 
response, which is evident from the higher initial 
values of the C reactive protein, the granulocytes, 
fibrinogen. They also have a longer hospital stay 
compared to the NE group, which is consistent with 
other studies [12]. In conclusion, erysipelas is more 
frequent in older people; it has a seasonal character 
with the highest peak in summer. Patients with 
recurrent erysipelas, located in the lower extremities, 
especially foot, with high temperature on admission, 
increased markers of inflammation, seem to be risk 
factors of prolonged hospital stay. 
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